Takashi Kumagai

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 300 citations

Medicine, Hematology, Oncology +4

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 117 citations · Full text

Medicine, Oncology, Pharmacology +9

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai et al. · The Lancet Haematology · 2020 · 101 citations

Medicine, Hematology, Pharmacology +5

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

Takashi Kumagai, Chiaki Nakaseko, Kaichi Nishiwaki et al. · Cancer Science · 2017 · 65 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Kazunori Murai, Hiroshi Ureshino, Takashi Kumagai et al. · The Lancet Haematology · 2021 · 64 citations

Medicine, Hematology, Pharmacology +8